These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31950924)

  • 1. Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
    Sahin A; Yildirim C; Yuksel OH; Urkmez A
    Arch Esp Urol; 2020 Jan; 73(1):54-59. PubMed ID: 31950924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
    Soliman MG; El-Abd SA; Tawfik AM; Radwan MH; El-Abd AS
    World J Urol; 2021 Jun; 39(6):2049-2054. PubMed ID: 32869151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms.
    Abdelaziz AS; Salama NM; Ghoneem AM
    World J Urol; 2022 Aug; 40(8):2113-2119. PubMed ID: 35760910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial.
    Chandna A; Kumar S; Parmar KM; Sharma AP; Devana SK; Mete UK; Singh SK
    Urologia; 2022 Nov; 89(4):589-596. PubMed ID: 34596484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
    Mueller ER; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Stoelzel M; Yoon SJ; Al-Shukri S; Rechberger T; Gratzke C
    Neurourol Urodyn; 2019 Feb; 38(2):779-792. PubMed ID: 30644570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
    Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
    Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
    Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
    Kakizaki H; Lee KS; Katou D; Yamamoto O; Sumarsono B; Uno S; Yamaguchi O
    Adv Ther; 2021 Jan; 38(1):739-757. PubMed ID: 33245533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study.
    Yavuz A; Kilinc MF; Aydin M; Ofluoglu Y; Bayar G
    Low Urin Tract Symptoms; 2021 Jan; 13(1):17-21. PubMed ID: 32408390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
    Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study.
    Tang QL; Zhou S; Liu YQ; Wu J; Tao RZ
    Sci Rep; 2022 Nov; 12(1):18844. PubMed ID: 36344629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
    Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.